Dana-Farber Cancer Institute shared a post on LinkedIn:
“‘Patients diagnosed with pancreatic cancer are living longer and living better. We are advancing into a greatly needed new era in pancreatic cancer treatment.’ — Brian Wolpin, MD, MPH, director of the Hale Family Center for Pancreatic Cancer Research
Nearly 95% of pancreatic cancers carry RAS gene mutations that drive tumor growth—and new drugs that target RAS are showing promise in clinical trials. These RAS inhibitors are paving the way for new treatments that could improve long-term outcomes for patients all around the world.
Advancements in pancreatic cancer care and research have been fueled by the generosity of Dana-Farber Trustee Judith B. Hale and members of her family, Rob and Karen Hale, and Beth and Rich Kendall. Their philanthropy supports our researchers in their efforts to advance early detection and develop new treatments for patients in Boston and around the world. Thanks to the work in the Hale Family Center for Pancreatic Cancer Research, we are learning more about and advancing new treatments for pancreatic cancer every day.”
More posts featuring Dana-Farber Cancer Institute.